- General Fusion became the first publicly listed fusion company following its
July 2026 listing on Nasdaq under the ticker symbol “GFUZ.” - Announced a world-first compressional plasma heating result with practical low-speed compression in October, exceeding 1 keV electron temperature (more than 12 million degrees Celsius) with Lawson Machine 26 (“LM26”) at commercially relevant scale, a key milestone on the path to commercializing fusion energy. The result was measured with the
United Kingdom Atomic Energy Authority (“UKAEA”) using gold-standard diagnostics. - Strong financial position with cash and short-term investments of
$140.9 million and a debt-free balance sheet as ofSeptember 30, 2026 . Capital in place is expected to fund the LM26 program through its final two technical milestones, 10 keV (100 million degrees Celsius), and the Lawson criterion1, through the end of 2028.
“General Fusion continues to lead on technology development, culminating in a landmark achievement when LM26 became the first fusion machine in the world to achieve 1 keV using practical, low-speed compression. Slower compression requires less power, reduces system complexity, and lowers costs, which are all hallmarks of our differentiated approach to commercialization,” said
Twinney continued, “General Fusion became the first publicly listed fusion company in
1 For General Fusion’s approach in LM26, achieving the Lawson criterion means simultaneously demonstrating, using deuterium-deuterium (
Financial Results2,3,4
- Cash and short-term investments were
$140.9 million as ofSeptember 30, 2026 . - Debt-free balance sheet.
- Operating loss (income) for the 3 and 9 months ended
September 30, 2026 , was$12.4 million and$40.5 million , an increase over the same periods in 2025 of$12.6 million and$30.4 million , respectively, mainly due to a large change in fair value of share-based compensation liability in Q3 2025 and government assistance received in 2025 with none in 2026. - Non-GAAP Adjusted Operating Loss for the 3 and 9 months ended
September 30, 2026 was$11.0 million and$29.5 million , an increase of$5.7 million or 108% and$10.5 million or 55% over the same periods in 2025, respectively.
General Fusion ended the third quarter of 2026 with
2 All financial figures in this release are presented in
3 Adjusted Operating Loss is a non-GAAP financial measure defined under “Non-GAAP Financial Measures” below.
4 The financial information presented below should be read in conjunction with the Company’s financial statements and accompanying notes included in its Form 6-K for the quarter ended
Looking Ahead
General Fusion remains focused on executing its staged commercialization roadmap. Near-term priorities include:
- Machine upgrades designed to compress our plasmas to higher density and temperatures as we advance the LM26 program toward 10 keV (100 million degrees Celsius) and, ultimately, the Lawson criterion1, supporting General Fusion’s objective of demonstrating commercially relevant fusion conditions.
- Progressing the Commercial Systems program to advance key systems and components for a commercial plant, including seals, valves, and heat exchange and pulsed power systems. Completion of this program is expected to support final machine design and the construction of a first-of-a-kind (“FOAK”) plant, with initial operations targeted around 2035.
- Expanding commercial, supply chain development, and strategic partnerships across energy, industrial, engineering, and technology ecosystems.
- Accelerating site evaluation and planning for the Commercial Systems program testbeds and FOAK plant supporting technical execution, commercial growth, and long-term scalability.
- Mapping a phased, flexible, capital efficient funding approach to the commercialization roadmap.
Webcast
General Fusion will host a conference call today,
A webcast replay of the call will be available for 12 months on the Events & Presentations page of General Fusion’s investor relations website.
| Interim Condensed Consolidated Balance Sheets (Unaudited) | ||||||
| Source: 3Q 2026 Earnings Press Release (GFUZ), | ||||||
| 2026 | 2025 | |||||
| Assets | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 105,567 | $ | 49,125 | ||
| Short-term investments | 35,254 | – | ||||
| Restricted cash | 306 | 667 | ||||
| Other receivables | 529 | 315 | ||||
| Prepaid expenses and other | 2,806 | 908 | ||||
| Total current assets | 144,462 | 51,015 | ||||
| Property and equipment | 4,423 | 6,424 | ||||
| Right-of-use assets | 2,660 | 2,918 | ||||
| Other assets | 37 | 37 | ||||
| Total assets | $ | 151,582 | $ | 60,394 | ||
| Liabilities, Temporary Equity and Shareholders' Deficiency | ||||||
| Current liabilities: | ||||||
| Accounts payable and accrued liabilities | $ | 5,003 | $ | 5,133 | ||
| Lease liabilities | 406 | 454 | ||||
| SRF contribution liability | 67,260 | 28,369 | ||||
| SAFE liabilities | – | 40,837 | ||||
| SAFE liabilities – related parties | – | 3,503 | ||||
| Total current liabilities | 72,669 | 78,296 | ||||
| Lease liabilities | 3,782 | 4,233 | ||||
| Share-based compensation | 4,284 | 15,545 | ||||
| Warrant liabilities | 51,296 | 13,171 | ||||
| Earnout liabilities | 74,411 | – | ||||
| Total liabilities | 206,442 | 111,245 | ||||
| Temporary equity: | ||||||
| Redeemable convertible multiple voting shares, 12,000,000 multiple voting shares authorized, 10,416,663 issued and outstanding (2025 – nil) | 128,390 | – | ||||
| Old General Fusion redeemable convertible preferred shares, nil issued and outstanding (2025 – 32,462,149) | – | 122,953 | ||||
| Shareholders' deficiency: | ||||||
| Subordinate voting shares, unlimited voting and non-voting shares authorized without par value, 53,132,058 shares issued and outstanding (2025 – nil) | 364,749 | – | ||||
| Old General Fusion common shares, no par value, nil issued and outstanding (2025 – 2,272,902) | – | 146,525 | ||||
| Additional paid-in capital | – | 18,327 | ||||
| Accumulated other comprehensive loss | (4,030 | ) | (6,704 | ) | ||
| Accumulated deficit | (543,969 | ) | (331,952 | ) | ||
| Total shareholders' deficiency | (183,250 | ) | (173,804 | ) | ||
| Total liabilities, temporary equity, and shareholders' deficiency | $ | 151,582 | $ | 60,394 | ||
| Interim Condensed Consolidated Statements of Operations and Comprehensive (Income) Loss (Unaudited) | |||||||||
| Source: 3Q 2026 Earnings Press Release (GFUZ), | |||||||||
| Three months ended | Nine months ended | ||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||
| Operating costs | |||||||||
| Research and development | |||||||||
| Business development, marketing, communications, and government relations | 1,222 | 885 | 3,556 | 2,458 | |||||
| General and administrative | 4,454 | (3,340 | ) | 16,294 | 539 | ||||
| Depreciation and amortization | 862 | 696 | 2,584 | 2,205 | |||||
| Government assistance | – | – | – | (5,921 | ) | ||||
| Operating loss (income) | 12,387 | (243 | ) | 40,498 | 10,128 | ||||
| Other Expense (Income) | |||||||||
| Interest expense | 14 | 224 | 38 | 1,149 | |||||
| Interest and other income | (1,172 | ) | (136 | ) | (1,866 | ) | (269 | ) | |
| Financing costs | 11,458 | – | 11,484 | – | |||||
| Foreign exchange loss (gain) | 2,055 | (86 | ) | 757 | (1,103 | ) | |||
| Gain on revaluation of convertible notes | – | (22,544 | ) | – | (22,036 | ) | |||
| Loss (gain) on revaluation of SRF contribution liabilities | (20,714 | ) | (18,026 | ) | 37,328 | (18,970 | ) | ||
| Loss (gain) on revaluation of SAFE liabilities | (2,778 | ) | – | 11,120 | – | ||||
| Loss (gain) on revaluation of PIPE subscription obligation | (1,769 | ) | – | 20,282 | – | ||||
| Gain on revaluation of warrant liabilities | (10,296 | ) | – | (7,952 | ) | – | |||
| Gain on revaluation of earnout liabilities | (19,384 | ) | – | (19,384 | ) | – | |||
| Net (income) loss before income taxes | $(30,199 | ) | $(40,811 | ) | $(31,101 | ) | |||
| Income tax expense | |||||||||
| Current | 41 | 22 | 41 | 22 | |||||
| Deferred | – | 3 | – | 3 | |||||
| Net (income) loss for the period | $(30,158 | ) | $(40,786 | ) | $(31,076 | ) | |||
| Other comprehensive (income) loss | |||||||||
| Foreign currency translation | 665 | (401 | ) | (2,674 | ) | 2,805 | |||
| Change in fair value of convertible notes attributable to changes in credit risk | – | – | – | (57 | ) | ||||
| Reclassification of changes in fair value of convertible notes attributable to changes in credit risk upon settlement | – | 347 | – | 347 | |||||
| Total other comprehensive (income) loss for the period | 665 | (54 | ) | (2,674 | ) | 3,095 | |||
| Total comprehensive (income) loss for the period | $(29,493 | ) | $(40,840 | ) | $(27,981 | ) | |||
| Net (income) loss per share – basic | $(27.59 | ) | $(45.26 | ) | |||||
| Net (income) loss per share – diluted | |||||||||
| Weighted average number of common shares outstanding – basic1 | 48,275,373 | 1,461,834 | 17,793,700 | 638,974 | |||||
| Weighted average number of common shares outstanding – diluted1 | 48,275,373 | 27,543,020 | 17,793,700 | 15,675,460 | |||||
1 The weighted average shares outstanding for the three month and nine month period ended
| Interim Condensed Consolidated Statements of Cash Flows (Unaudited) | ||||||
| Source: 3Q 2026 Earnings Press Release (GFUZ), | ||||||
| Nine Months Ended | ||||||
| 2026 | 2025 | |||||
| Cash flows from operating activities: | ||||||
| Net (loss) income for the period | $ | (92,346 | ) | $ | 31,076 | |
| Adjustments: | ||||||
| Depreciation and amortization | 2,584 | 2,205 | ||||
| Gain on disposal of assets | – | (10 | ) | |||
| Share-based compensation | 8,419 | (5,144 | ) | |||
| Loss (gain) on revaluation of SRF contribution liability | 37,328 | (18,970 | ) | |||
| Loss on revaluation of SAFE liabilities | 11,120 | – | ||||
| Loss on revaluation of PIPE subscription obligation | 20,282 | – | ||||
| Gain on revaluation of convertible notes | – | (22,036 | ) | |||
| Gain on revaluation of warrant liabilities | (7,952 | ) | – | |||
| Gain on revaluation of Earnout liabilities | (19,384 | ) | – | |||
| Share consideration expensed | 9,251 | – | ||||
| Interest expense | – | 1,124 | ||||
| Interest paid | – | (1 | ) | |||
| Deferred income tax | – | 3 | ||||
| Unrealized foreign exchange loss (gain) | 1,077 | (952 | ) | |||
| Changes in operating assets and liabilities: | ||||||
| Other receivables | (220 | ) | 97 | |||
| Prepaid expenses and other | (2,051 | ) | 248 | |||
| Accounts payable and accrued liabilities | (373 | ) | (1,926 | ) | ||
| Lease liabilities and right of use assets | (351 | ) | (59 | ) | ||
| (32,616 | ) | (14,345 | ) | |||
| Investing activities: | ||||||
| Additions to property and equipment | (551 | ) | (172 | ) | ||
| Purchase of short-term investments | (35,291 | ) | – | |||
| (35,842 | ) | (172 | ) | |||
| Financing activities: | ||||||
| Proceeds from reverse recapitalization and | 123,330 | – | ||||
| Proceeds from issuance of redeemable convertible preferred shares | – | 17,020 | ||||
| Proceeds from issuance of SRF Warrants | 3,624 | 4,570 | ||||
| Proceeds from issuance of SAFE liabilities | 200 | – | ||||
| Proceeds from short-term loan | – | 1,400 | ||||
| Proceeds from exercise of stock options | 20 | 2 | ||||
| Share issuance costs on SAFE issuance | (27 | ) | (20 | ) | ||
| 127,147 | 22,972 | |||||
| Effect of foreign exchange rates on cash and cash equivalents | (2,608 | ) | 208 | |||
| Increase (decrease) in cash and cash equivalents, and restricted cash | 56,081 | 8,663 | ||||
| Cash and cash equivalents, and restricted cash, beginning of period | 49,792 | 6,561 | ||||
| Cash and cash equivalents, and restricted cash, end of period | $ | 105,873 | $ | 15,224 | ||
Non-GAAP Financial Measures
This news release makes reference to a financial measure not recognized under
General Fusion’s management uses this measure to assess General Fusion’s performance, identify trends affecting General Fusion’s business, formulate business plans, and make strategic decisions.
Adjusted Operating Loss should be considered in addition to, not as a substitute for or in isolation from, our financial results prepared in accordance with GAAP. In addition, our presentation of Adjusted Operating Loss may be different from how such a metric is used by other companies.
A reconciliation of Adjusted Operating Loss to Operating loss (income) from the Interim Condensed Consolidated Statements of Operations and Comprehensive (Income) Loss for the three and nine months ended
| Three months ended | Nine months ended | ||||||||||||
| (in thousands of dollars, except percentages) | 2026 | 2025 | % Change | 2026 | 2025 | % Change | |||||||
| Operating loss (income) | $(243 | ) | n/m | 300 | % | ||||||||
| Share-based compensation | (480 | ) | 6,244 | (108 | )% | (8,419 | ) | 5,144 | (264 | )% | |||
| Government assistance | – | – | n/m | – | 5,921 | n/m | |||||||
| Depreciation and amortization | (862 | ) | (696 | ) | 24 | % | (2,584 | ) | (2,205 | ) | 17 | % | |
| Adjusted Operating Loss | 108 | % | 55 | % | |||||||||
n/m = not meaningful
About General Fusion
General Fusion (NASDAQ: GFUZ) is a fusion technology development company. The Company aims to deliver economical, carbon-free fusion energy through its practical Magnetized Target Fusion (“MTF”) technology, an engineering-driven approach to fusion energy. General Fusion’s commercialization program is anchored by LM26, the world’s first commercially relevant-scale MTF demonstration machine. The Company is working toward the commercial deployment of fusion power in the mid-2030s. General Fusion is the first publicly listed fusion company and TIME’s No. 1
Investor Relations Contact
Contact General Fusion’s Investor Relations team at: investors@generalfusion.com.
If you are based in
Media Relations Contact
media@generalfusion.com
1-866-904-0995
Cautionary Note Regarding Forward-Looking Statements
Certain statements included in this news release are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995 and forward-looking information within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). All statements other than statements of historical facts contained in this news release are forward-looking statements. Any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are also forward-looking statements. In some cases, you can identify forward-looking statements by words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “strategy,” “future,” “opportunity,” “may,” “target,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” “preliminary,” or similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements include, without limitation, statements regarding its ability to commercialize MTF or any other fusion technology on its expected timeline or at all; and statements regarding the current and expected results of the LM26 program; as well as any information concerning possible or assumed future results of operations or financial position of the Company.
These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions, many of which are beyond the control of the Company.
These forward-looking statements involve a number of risks, uncertainties, or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company is unable to maintain the listing of its securities on Nasdaq; the risk that the price of the Company’s securities may be volatile due to a variety of factors outside of the Company’s control, the risk that the Company never generates revenue, the risk that the Company fails to commercialize MTF on a cost-effective basis, on the expected timeline or at all, the risk that the Company fails to achieve the objectives of the LM26 program, the risk that the technical results disclosed herein are not accepted or validated by the scientific community; the risk that prior results are not successfully repeated on a larger scale; the risk that the scientific and technical assumptions underlying the results described herein prove to be incorrect; the risk that recent technical results do not prove to be as significant to the operation of LM26 as expected; the risk that the anticipated cost of funding the LM26 program across several planned technical milestones through the end of 2028 is greater than anticipated and additional capital needed by the Company may not be raised on favorable terms, or at all, including as a result of the restrictions agreed to in connection with the private placement the Company closed on
These forward-looking statements are based on certain assumptions, including that none of the risks identified above materialize; that there are no unforeseen changes to economic and market conditions, and that no significant events occur outside the ordinary course of business.
The foregoing list is not exhaustive, and there may be additional risks that the Company does not know or currently believes are immaterial. You should carefully consider the foregoing factors, any other factors discussed herein and in the other filings by the Company with the U.S. Securities and Exchange Commission and on SEDAR+, including those described under the heading “Risk Factors.” The Company does not undertake to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required in accordance with applicable laws.
Source: General Fusion